EGFR G796D mutation mediates resistance to osimertinib

Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). Despite impressive initial tumor responses, development o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Zheng, Di, Hu, Min, Bai, Yu, Zhu, Xuehua, Lu, Xuesong, Wu, Chunyan, Wang, Jiying, Liu, Li, Wang, Zheng, Ni, Jian, Yang, Zhenfan, Xu, Jianfang
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564797/
https://ncbi.nlm.nih.gov/pubmed/28572531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17913
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares